drugset / Trial / NCT01597895

Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects

NCT01597895

Phase 1 Completed 14 enrolled ViiV Healthcare Pfizer · collab
Non-randomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to determine the effect that telaprevir and boceprevir has on the pharmacokinetics of maraviroc.

Timeline

Start
2012-07
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Boceprevir Small molecule 800 mg
Comparator Maraviroc Other / unclassified 150 mg
Subject Telaprevir Small molecule 800 mg

Indications

No indication recorded.